Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Given as a Booster to Those Previously Vaccinated Against SARS-CoV-2

NCT05182567 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT05182567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05182567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Given as a Booster to Those Previously Vaccinated Against SARS-CoV-2
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
May 23, 2022
Completion date
December 31, 2023
Enrollment
69 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, healthy